BRIEF — Takeda closes deal for TiGenix

Japanese pharma major Takeda has taken a step towards adding more innovative therapies to its portfolio in gastrointestinal disorders by formally closing the deal to take over TiGenix.

Both companies involved have announced that, at the close of the first acceptance period of the bid, Takeda has secured 90.83% of the voting rights of the Belgian drugmaker. The conditions of the bid have been satisfied and the deal has closed.

The takeover bid, worth around $630 million, was first announced in January of this year.